| abstract |
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises the administration of at least two direct-acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include the administration of interferon or ribavirin, and said At least two direct-acting antiviral agents comprise (a) compound 1 or a pharmaceutically acceptable salt and (b) compound 2 or a pharmaceutically acceptable salt. |